Pfizer reports positive data from new Champix trial

Pfizer has published new clinical data showing how its product Champix can make it easier for smokers to quit the habit than traditional cessation aids.

Patients trialled using Champix have been shown to be significantly more likely to quit smoking and continue to abstain than those using nicotine replacement therapy (NRT) patches.

The varenicline therapy was also associated with a better rate of success than combination NRT options, defined as nicotine patches plus one additional acute formulation of gum, lozenge, inhaler or nasal spray.

Champix is already approved by the UK's National Institute for Health and Clinical Excellence as a first-line smoking cessation therapy.

Lead study author Dr Edward Mills, of the department of clinical epidemiology and biostatistics at McMaster University, said: "This analysis clearly demonstrates varenicline's effectiveness compared to standard dose, high dose and combinations of NRT."

Earlier this week, the company published positive data from a phase IV clinical trial of Toviaz, its US-approved treatment for overactive bladder patients.